[ENDO2013]奥培米芬显著改善女性性功能障碍
发布时间:2013-06-27   |   来源:医脉通
关键词: 奥培米芬 女性 性功能障碍 ENDO2013
【导语】第95届美国内分泌学会年会(ENDO2013)于2013年6月15-18日在美国旧金山隆重举行。大会旨在为内分泌领域研究人员提供最前沿的科学知识与技术,包括基础和临床研究。本次大会参会人数达9300位,创ENDO年会历史新高,共收到摘要约2600份,ENDO2013希望与会者能从中获得有价值的教育内容和发现新的有启发性的想法以促进临床实践。医脉通精选部分会议亮点研究以飨读者!


  一项多中心、随机、安慰剂对照、III期临床试验分析结果显示,奥培米芬60mg治疗可显著改善女性性功能障碍患者的女性性功能指数(FSFI)总分。

  奥培米芬是一种组织选择性、非甾体雌激素受体激动剂/拮抗剂,最近被批准用于治疗因更年期引起的性交困难、外阴炎及阴道萎缩(VVA)等。有报道认为绝经后性交困难和女性性功能障碍(FSD)有关。女性性功能指数(FSFI)是一份包括19项题的问卷调查,已作为一种患者自评的工具被广泛应用。FSFI分6项进行打分(唤起、性欲、高潮、润滑、满意度以及性交疼痛)。用奥培米芬60mg治疗依据FSFI评估认为的性功能障碍患者,并进行临床数据分析来评估药物疗效。
 
  这项临床试验采用随机、双盲、平行对照来比较口服奥培米芬与安慰剂的有效性、安全性和耐受性。共919名妇女(奥培米芬组463名,安慰剂组456名),年龄在40-80岁之间。依据患者自评的最严重症状(MBS),如阴道萎缩所致的性交困难或阴道干燥等,将患者分为2组,分别给予奥培米芬 60mg 1次/日 或安慰剂治疗,共12周。独立分析每一组数据。阴道润滑剂可随时使用。主要联合终点是表层细胞和基地旁细胞成熟指数(MI)、阴道PH值和最严重症状(MBS)从基线到12周的变化。次要疗效终点是女性性功能指数(FSFI)总分和FSFI问卷中 6项的患者自评分值从基线到4周及12周的变化。
 
  性功能评估结果显示:与安慰剂组相比,在第12周时,奥培米芬组患者的FSFI问卷的6项分值(性欲、唤起、润滑、高潮、满意度以及性交疼痛)及总分得到明显改善,有统计学意义。在第4周时,奥培米芬组患者除高潮和满意度2项外,其他4项都得到显著改善。
 
  FSFI问卷中6项分值得到一致的观察结果,是奥培米芬与其他治疗性交困难药物在疗效上的主要区别。
 

 【研究摘要】
Ospemifene Significantly Improves Female Sexual Dysfunction As Measured By the Female Sexual Function Index (FSFI): Results of a Randomized Placebo Controlled Trial
Ginger D Constantine*1, Jay J Constantine1, Michele Giliberti2 and Shelli Graham2
1EndoRheum Consultants, Media, PA,2Shionogi, Inc, Florham Park, NJ

Background:Ospemifene is a tissue selective, non-steroidal estrogen receptor agonist/antagonist that was recently approved for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), due to menopause. Postmenopausal dyspareunia has been reported to be associated with female sexual dysfunction (FSD). The Female Sexual Function Index (FSFI), a 19-item questionnaire, is a widely used patient self-reported outcome tool that scores 6 domains (arousal, desire, orgasm, lubrication, satisfaction, and pain). Clinical trial data were analyzed to determine the effect of ospemifene 60 mg on FSD as assessed by the FSFI.

Methods:A multicenter phase 3 trial used a randomized, double-blind, parallel-group design to compare the efficacy, safety, and tolerability of oral ospemifene 60 mg versus placebo. A total of 919 women (ospemifene, n=463; placebo, n=456), aged 40 to 80 years, were assigned to one of 2 VVA symptom strata, based on self-reported most bothersome symptom (MBS) of dyspareunia or dryness, to receive a once-daily dose of ospemifene 60 mg or placebo for 12 weeks. Data from each stratum were independently analyzed. A vaginal lubricant was provided for use as needed. Co-primary endpoints were change from Baseline to Week 12 (LOCF) in: % superficial cells and % parabasal cells in the Maturation Index (MI), vaginal pH, and MBS. A secondary efficacy endpoint measured mean changes from Baseline to Weeks 4 and 12 (LOCF) for FSFI total score and for each of the 6 domains based on patient-assessed sexual function in the FSFI questionnaire. This abstract reports the sexual function assessment results.

Results: Statistically significant (p<0.05) improvements for ospemifene 60 mg vs placebo were seen for every FSFI domain score (desire, arousal, lubrication, orgasm, satisfaction, and pain) and the total score at Week 12 (LOCF). At Week 4, every domain was significantly improved except for orgasm (p=0.0820) and satisfaction (p=0.3206).

Conclusion: In a randomized, placebo-controlled clinical trial, ospemifene 60 mg was shown to significantly improve FSD in the total FSFI score. Significant improvement was also seen in 4 of the domains at Week 4 and in all 6 domains at Week 12 of treatment. Consistency of effect was observed in all of the domains, which distinguishes ospemifene from other agents that treat dyspareunia. Confirmation of this data and assessment as to whether these effects are related solely to the improvement in dyspareunia remains to be elucidated.
(本网站所有内容,凡注明来源为"医脉通",版权均归医脉通所有,未经授权,任何媒体、网站或个人不得转载,否则将追究法律责任,授权转载时须注明"来源:医脉通"。本网注明来源为其他媒体的内容为转载,转载仅作观点分享,版权归原作者所有,如有侵犯版权,请及时联系我们。)
0
收藏
添加表情
全部评论
我要投稿
发表评论
扫码分享

微信扫码分享

回到顶部